Forty-two patients allografted for multiple myeloma after not having attained at least a partial remission (n = 19) or after having experienced disease progression (n = 23) following one autograft were compared with 42 pair-matched controls who underwent salvage autotransplantation under identical conditions. Autografted controls were matched closely for albumin, C-reactive protein, creatinine, disease sensitivity, duration of standard therapy prior to the first transplant, Ig isotype, karyotype, LDH, and response to the first transplant, but, in comparison to allografted patients, were older, had higher ␤2-microglobulin, and had a shorter interval between the two transplants. The complete remission rate was 41% after allogeneic and 33% after autologous transplantation (P ‫؍‬ NS). The 3-year probability of event-free survival was comparable for the two groups (25 ؎ 8% after autografting and 20 ؎ 8% after allografting). The 3-year probability of survival was significantly higher after autologous transplantation (54 ؎ 8% vs 29 ؎ 9%; P ‫؍‬ 0.01). Twenty-one patients in the autograft group were alive 11-59 months (median 32) following the second transplant, while 15 patients in the allograft group were alive at 10-53 months (median 20). The 3-year probability of disease progression was significantly lower after allogeneic transplantation (31 ؎ 10% vs 72 ؎ 9%, P ‫؍‬ 0.03). The 1-year probability of transplant-related mortality was significantly higher after allografting (43 ؎ 8% vs 10 ؎ 5%; P ‫؍‬ 0.0001). We conclude that while autografting appears to be superior to allografting for salvage therapy of myeloma persisting or relapsing after one previous autotransplant in terms of overall survival, eventfree survival is comparable due to significantly lower disease progression after allografting. Reduction in allograft-related toxicity can potentially improve the results of allogeneic transplantation significantly.
Conventional chemotherapy results in complete remission (CR) in no more than 5% of patients with multiple myeloma, and survival beyond 10 years in only 5%. 1 High-dose chemotherapy with or without autologous hematopoietic stem cell support increases response rates in myeloma, [2] [3] [4] and 40-50% of newly diagnosed patients attain complete remission after sequential intensive therapy including two autografts. 5 The outcome of autografted patients is superior to those receiving conventional chemotherapy. 6, 7 Rapid engraftment with blood-derived stem cells 8 and improved supportive care 9 have made autologous transplantation very safe with treatment-related mortality rates of 1-3%. 6, 9 However, many patients eventually relapse following autotransplantation. 10, 11 Allogeneic bone marrow transplantation (BMT) can result in long-term molecular remission of myeloma, 12 but it has been associated with high treatment-related mortality. [13] [14] [15] A recent study from the European Group for Blood and Marrow Transplantation (EBMT) showed that although the probability of disease progression was significantly lower after allogeneic BMT than after autologous transplant, the transplant-related mortality was much lower after autografting and, consequently, overall survival was significantly superior after autografting. 16 Our strategy has been largely to confine the use of allogeneic transplantation to patients failing to attain at least a partial remission after one autograft or to those progressing after one autograft before the second scheduled autograft, ie patients in whom further autologous transplantation may be expected to have a limited role. The aim of this retrospective pair-matched study was to compare the outcome of autologous vs allogeneic transplantation as salvage therapy in these patients.
Patients and methods
The study group comprised 42 multiple myeloma patients who underwent allogeneic transplantation at the University of Arkansas for Medical Sciences between 1992 and 1996 after failing to attain at least a partial remission or progressing after one autograft. The control group comprised 42 patients who were autografted under similar clinical (disease) circumstances. Because of the relatively advanced age of most patients with myeloma and the limited availability of suitably HLA-matched donors, we have perfor-med second autografts as salvage therapy for disease progression.
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Selection of matched controls
The 42 matched control patients (Table 1) were derived from a population of 360 tandem autotransplant patients who had complete data (all variables specified below) available for matching. Matching was performed using a standardized Euclidian distance measure 17 comprising the following prognostic factors: albumin, ␤2-microglobulin and LDH prior to the second transplant, interval between the two transplants, and the karyotype at presentation. The choice of prognostic factors for matching was based partly upon our experience of factors which affect the outcome of autografted (␤2-microglobulin, karyotype and interval between the two transplants) 5 and allografted (albumin and LDH) 15 myeloma patients. Each allograft patient was compared iteratively with each tandem autograft recipient. A match was selected from the minimum distance achieved between an allograft and an autograft recipient over the entire iteration. 17 When an autograft recipient was the best match for more than one allograft recipient, the autograft recipient with the next smallest distance measure for the allograft recipient in question was chosen as the control.
Conditioning regimens
The conditioning regimen for the first autograft was 200 mg/m 2 melphalan for all 84 patients. The conditioning regimens for allogeneic transplantation are shown in Table 2 
Supportive therapy
All patients were treated in single rooms with positivepressure ventilation. Blood products transfused were not screened for cytomegalovirus (CMV) antibody, but were leukocyte-depleted using filters. An attempt was made to maintain the hemoglobin over 8 g/dl and platelets over 20 × 10 9 /l. Fever during the neutropenic phase was treated with broad-spectrum antibiotics and amphotericin as necessary.
Statistical analysis
The data were analyzed as of 28 February 1997. Categorical variables were compared using Fisher's exact test and continuous variables using the Wilcoxon rank-sum test. The probabilities of overall survival, event-free survival, disease progression and transplant-related mortality were estimated using the method of Kaplan and Meier, and the distributions compared using the log-rank test. Overall survival was measured from second transplant to death or last follow-up if alive. Event-free survival was measured from second transplant to disease progression, death, or the last follow-up without disease progression. For the purposes of estimating event-free survival and disease progression, patients who had active disease at the time of the transplant which never responded were plotted as failures from the time of transplant.
The following variables were analyzed in multivariate fashion using a Cox proportional hazards model for their effect on the probabilities of overall survival, event-free survival, disease progression and transplant-related mortality for all 84 patients: age, Ig isotype, karyotype, duration of standard therapy prior to the first transplant, response to the first transplant (CR or PR vs no response), the type of second transplant (autograft or allograft), interval between the two transplants and albumin, ␤2-microglobulin, Creactive protein, creatinine and LDH at the time of the second transplant. Table 1 shows that characteristics of the two groups of patients were comparable except that the autograft recipients tended to be older, had higher ␤2-microglobulin levels, and had their second transplants at a shorter interval after the first.
Results
Transplant-related toxicity
Four patients in the autograft group died of transplantrelated toxicity at 1 week to 4.5 months (median 1.5) compared with 21 in the allograft group at 3 weeks to 47 months (median 4.5). Transplant-related mortality at 1 year was significantly higher after allografting (43 ± 8% vs 10 ± 5%, P = 0.0001, Figure 1 ). Four deaths occurred in the allograft group beyond 1 year as a result of chronic graftversus-host disease (GVHD) and opportunistic infections.
Disease response
Of the 13 patients who died within 2 months and were considered non-responders, 10 were allografted and three were autografted. As Table 3 shows, there was a trend towards a higher overall response rate (CR and PR) in the autograft group.
Disease progression
Twenty-six patients in the autograft group, including five with active disease at the time of transplant who did not respond to the salvage transplant at all, experienced disease progression at 0-54 months (median 12.5) after transplantation; 16 died of recurrent disease or toxicity of salvage therapy and 10 are alive with progressive disease. Eight patients in the allograft group, including one with active disease at the time of the transplant who did not respond to the transplant, experienced disease progression at 0-19 months (median 5.5) after the transplant; five died of recurrent disease or toxicity of salvage therapy and three are alive with progressive disease. The probability of disease progression at 3 years was significantly lower after allogeneic transplantation (31 ± 10% vs 72 ± 9%, P = 0.03, Figure 2 ). There was no progression seen in the allograft 889 All parameters represent values at the time of the second transplant unless otherwise specified. group beyond 20 months whereas progressive disease continued to be seen among autografted patients over 4 years following the transplant (Figure 2 ).
Other deaths
One patient in the allograft group, who was otherwise well except for limited chronic GVHD, died suddenly at 33 months after strenuous exertion. This patient was censored at the time of death for calculating probabilities of disease progression and transplant-related mortality, and was considered an event (failure) for event-free survival and overall Patients dying early within 2 months (n = 13; 10 in the allograft group and three in the autograft group) have been considered non-responders. survival. One patient in the autograft group developed acute myeloid leukemia (AML) with a normal karyotype 48 months after autograft with no evidence of recurrent myeloma, received remission induction chemotherapy and underwent a third autograft. He died 2 months after the third autograft whilst thrombocytopenic with no evidence of residual myeloma or AML. This patient was censored at the time of the diagnosis of leukemia for calculating the probabilities of disease progression and transplant-related mortality, and was considered an event (failure) at the time of development of AML for event-free survival and at the time of death for overall survival.
Survival
Twenty-one patients in the autograft group were alive at the last follow-up 11-59 months (median 32) following the second transplant. Fifteen patients in the allograft group were alive at the last follow-up 10-53 months (median 20) following the second transplant. The 3-year probability of survival was higher for the autograft group (54 ± 8% vs 29 ± 9%, P = 0.013, Figure 3 ). Eleven patients in the autograft group are alive in complete (n = 7) or partial (n = 4) remission, and 12 allograft recipients are alive in complete (n = 6) or partial (n = 6) remission. The 3-year probability of event-free survival was comparable for the two groups (25 ± 8% vs 20 ± 8%, P = 0.3, Figure 4 ). 
Multivariate analysis of outcomes
As summarized in Table 4 , allogeneic transplantation was associated with significantly lower probabilities of survival and disease progression, and a higher probability of treatment-related death. Low C-reactive protein (Ͻ4 mg/l), low LDH (р190 U/l), and high albumin levels (Ͼ3.5 g/dl) at the time of the second transplant also influenced the outcome favorably (Table 4 ). Achievement of CR or PR following the first transplant influenced the event-free survival favorably, but had no effect on disease progression, transplant-related mortality or overall survival. A shorter interval between two transplants influenced transplant-related mortality, and overall and event-free survival favorably.
Discussion
Our data show that even in patients who have failed a previous autograft (a population in which further autotransplantation may be expected to have a limited role), autologous transplantation resulted in a 4-year survival of 50%. This was better than the overall survival observed after allogeneic BMT. The major reason for the difference was the significantly higher transplant-related mortality in the allograft group. However, the probability of disease progression was significantly lower after allogeneic transplantation, resulting in comparable event-free survival in both groups. The other parameters found to influence outcome in the entire group were biologic variables such as LDH, C-reactive protein and albumin. The three variables (age, ␤2-microglobulin and interval between the two transplants) which were not comparable for the two groups in fact did not affect the overall outcome in multivariate analysis. Our findings are in agreement with those of a recent EBMT study of single transplants 16 which showed significantly superior overall survival after autografting (median 34 months compared with 18 months after allografting) as a result of much lower transplant-related mortality (13% compared with 41% after allografting, P = 0.0001). However, there is a crucial difference in the patient groups studied: the patients in the EBMT analysis had not been autografted previously. With up to 16% survival reported at 10 years in selected myeloma patients treated with high-dose therapy, 18 it is not surprising to see that autografted patients fared better than allografted patients in the EBMT study; Table 4 Multivariate analysis of prognostic factors at least over the medium term. 16 Our study included only patients who had already failed one autograft. It is more surprising to see the difference between auto-and allografting in patients who have failed to attain at least a PR or have progressed following the first transplant.
Allogeneic transplantation is associated with an immunologic graft-versus-myeloma effect. [19] [20] [21] It would therefore be expected to result in much lower rates of disease recurrence. A lower probability of disease recurrence was seen amongst allografted patients beyond 1 year from transplantation in the EBMT study. However, even with a median follow-up of 46 months, a plateau was not seen in the event-free survival among allografted patients due to a number of relapses beyond 5 years (three relapses after 7 years). It is possible that these patients may have relapsed earlier, but the relapse was not detected earlier because patients were asymptomatic or were lost to regular followup. In our patients, no disease progression has been seen in allografted patients beyond 29 months 15 (20 months in the current population) with monthly follow-up through mailed-in specimens and formal evaluation at 3-6-month intervals. However, the median follow-up in our group of patients is not long enough, and later relapses may be detected with longer follow-up. It is possible that if the difference in disease progression between allografted and autografted patients is maintained over a longer follow-up period, the proportion of long-term survivors in the two groups will be similar.
Unlike in the larger studies, 14, 15 transplant-related toxicity has not been a major problem in smaller reports utilizing less toxic conditioning regimens in patients with chemosensitive disease. [22] [23] [24] [25] One of our concerns has been the contribution of the preceding autograft to transplantrelated mortality with the subsequent allograft. An analysis of our complete allograft population showed no difference in toxic deaths amongst patients autografted previously and those not autografted in the past. 15 The actual toxic death rate of allografted patients in our study (50%; 21 of 42) is not very different from the Seattle report 14 (58%; 46 of 80)
or from the EBMT data 15 (41%; 77 of 189; P = 0.17, Chisquare test) on patients who had not been transplanted before. The Seattle and EMBT data show that the extent of prior therapy does contribute to mortality. 14, 26 This issue remains unresolved.
Decreasing the intensity of the conditioning regimen could potentially reduce transplant-related toxicity. Relatively modest changes in the conditioning regimen can sometimes improve toxicity remarkably: in acute myeloid leukemia patients allografted in first remission from HLAidentical siblings, a change in the dose of the TBI from 1050 cGy to 950 cGy decreased the number of toxic deaths within the first 4 months from 25% (nine of 36) to zero (none of 11; P = 0.07). 27 Kulkarni et al 25 reported 24 patients (67% with responsive disease); 20 of whom were conditioned with 110 mg/m 2 melphalan and 950 or 1050 cGy single-fraction TBI. There was a trend for more intensively conditioned patients (higher TBI dose) to have higher early mortality: eight of 13 patients (62%) receiving 1050 cGy TBI died of toxicity within 100 days compared with three of the other 11 (27%).
Our current approach to decreasing transplant-related toxicity has focused on decreasing the dose of the TBI whether the marrow is depleted of T cells or not, and on the replacement of methylprednisolone with cyclosporine for prevention of graft rejection after T cell-depleted grafts. The preliminary results (unpublished data) appear to show a marked improvement with decreased early mortality.
Another potential benefit of allogeneic transplantation could be the avoidance of myelodysplasia and secondary AML seen in autografted patients 28 due to reconstitution with normal hematopoietic stem cells.
In conclusion, autografting appears to be superior to allografting for salvage therapy of myeloma persisting or relapsing after one previous autotransplant in terms of overall survival. However, event-free survival is comparable due to significantly lower disease progression after allografting. These observations may change with longer follow-up as autografted patients continue to relapse.
